Ubenimex, an oral dual-inhibitor developed by Eiger BioPharmaceuticals, has failed to demonstrate its effectiveness to treat pulmonary arterial hypertension (PAH) in the Phase 2 LIBERTY study. Initiated in 2016, the LIBERTY trial (NCT02664558) included 61 patients with diagnosed WHO Group 1 PAH across 45 clinical sites in…
News
A tool for estimating blood pressure on the left side of the heart is unable to predict the long-term survival of pulmonary hypertension patients taking Remodulin, a study reports. The tool, pulmonary capillary wedge pressure, or PCWP, is used to estimate blood pressure in the left atrium. United Therapeutics makes …
French scientists have identified antibodies that appear to increase the risk of a poor outcome in pulmonary arterial hypertension patients with lupus and others they believe improve patients’ survival. Anti-SSA/SSB antibodies are a risk factor in PAH patients with systemic lupus erythematosus, or SLE, while anti-U1-RNP antibodies are associated with a…
United Therapeutics and Corsair Pharma are teaming up to advance Corsair’s development of a blood-vessel-widening skin patch for treating pulmonary arterial hypertension. The patch will contain treprostinil, which is already available in other forms. Both companies have been working on ways to improve the administration of the compound. United developed a…
Using a multi-category index to assess pulmonary hypertension patients’ response to Adempas (riociguat) can help doctors predict their survival, a study reports. REVEAL risk scores can also help doctors predict patients’ progression-free survival — or the length of time it takes for their disease to worsen, researchers said. The study, which…
Liquidia Technologies has started a Phase 3 clinical trial to evaluate LIQ861 as a treatment for pulmonary arterial hypertension. LIQ861 is a dry-powder, inhaled formulation of treprostinil that Liquidia developed to deliver deep into the lungs. U.S. regulators have already approved other formulations of treprostinil, which is a synthetic version…
Bellerophon Therapeutics has enrolled the first patient in a Phase 2b clinical trial evaluating INOpulse as a treatment for pulmonary hypertension associated with interstitial lung disease, or PH-ILD. The trial (NCT03267108) will assess the safety and effectiveness of Bellerophon’s pulsed, inhaled nitric oxide treatment for people with PH-ILD, including…
Important research findings, therapy advances, and other events related to pulmonary hypertension were reported daily in Pulmonary Hypertension News during 2017. Now that the year is over, it’s time to briefly review the articles that appealed most to our readers. Here are the Top 10 most-read articles of 2017, with a brief description of…
A group of clinician-researchers with expertise in the field of cardiovascular and pulmonary diseases propose in a commentary that guidelines for the diagnosis of pulmonary hypertension (PH) should be changed to include patients who may be at risk of developing the disease. The researchers contend that a broader definition of PH…
Tracleer (bosentan) may be of significant benefit to people with borderline or less severe pulmonary hypertension (PH) due to idiopathic pulmonary fibrosis (IPF), results from an ongoing clinical trial suggest. According to interim data collected from the Japanese study, Tracleer — an approved therapy for pulmonary…
The first healthy participants have been injected with CAM2043 (treprostinil FluidCrystal Injection Depot) in a Phase 1 study assessing the treatment’s safety, tolerability, and pharmacokinetics in both single and repeated doses, the Swedish pharmaceutical company Camurus announced. CAM2043 contains treprostinil, a therapy that is effective for treating pulmonary…
A report about life with pulmonary arterial hypertension (PAH) as a young person, created by young patients worldwide, addresses issues both pertinent and challenging to this age group — 18 to 30 — whose particular needs beyond the physical can often be overlooked. These issues range from choosing a…
